Literature DB >> 32747501

Protective Immune Responses Elicited by Deglycosylated Live-Attenuated Simian Immunodeficiency Virus Vaccine Are Associated with IL-15 Effector Functions.

Satoru Watanabe1, Masayuki Fujino1, Yohei Saito1,2, Nursarat Ahmed1, Hirotaka Sato1, Chie Sugimoto3, Tomotaka Okamura2, Kenichi Hanaki4, Emi E Nakayama5, Tatsuo Shioda5, Kouji Matsushima6, Aftab A Ansari7, Francois Villinger8, Kazuyasu Mori9,2,6.   

Abstract

Deglycosylated, live-attenuated SIV vaccines elicited protective immune responses against heterologous SIVsmE543-3, which differs from the vaccine strain SIVmac239 to levels similar to those across HIV-1 clades. Two thirds of the vaccinees contained the chronic SIVsmE543-3 infection (controllers), whereas one third did not (noncontrollers). In this study, we investigated immune correlates of heterologous challenge control in rhesus macaques of Burmese origin. Because depletion of CD8+ cells in the controllers by administration of anti-CD8α Ab abrogated the control of viral replication, CD8+ cells were required for the protective immune response. However, classical SIV-specific CD8+ T cells did not account for the protective immune response in all controllers. Instead, IL-15-responding CD8α+ cells, including CD8+ T and NK cells, were significantly higher in the controllers than those in the noncontrollers, before and after vaccination with deglycosylated SIV. It is well established that IL-15 signal transduction occurs through "trans-presentation" in which IL-15 complexed with IL-15Rα on monocytes, macrophages, and dendritic cells binds to IL-15 Rβ/γ expressed on CD8+ T and NK cells. Accordingly, levels of IL-15 stimulation were strongly affected by the depletion of monocytes from PBMCs, implying key roles of innate immune cells. These results suggest that intrinsic IL-15 responsiveness may dictate the outcome of protective responses and may lead to optimized formulations of future broadly protective HIV vaccines.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32747501      PMCID: PMC7484436          DOI: 10.4049/jimmunol.1901431

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

Review 2.  Natural SIV hosts: showing AIDS the door.

Authors:  Ann Chahroudi; Steven E Bosinger; Thomas H Vanderford; Mirko Paiardini; Guido Silvestri
Journal:  Science       Date:  2012-03-09       Impact factor: 47.728

Review 3.  HIV vaccine design: insights from live attenuated SIV vaccines.

Authors:  Wayne C Koff; Philip R Johnson; David I Watkins; Dennis R Burton; Jeffrey D Lifson; Kim J Hasenkrug; Adrian B McDermott; Alan Schultz; Timothy J Zamb; Rosanne Boyle; Ronald C Desrosiers
Journal:  Nat Immunol       Date:  2006-01       Impact factor: 25.606

Review 4.  A brief history of the global effort to develop a preventive HIV vaccine.

Authors:  José Esparza
Journal:  Vaccine       Date:  2013-05-21       Impact factor: 3.641

Review 5.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 6.  Redefining the viral reservoirs that prevent HIV-1 eradication.

Authors:  Evelyn Eisele; Robert F Siliciano
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

7.  Glycosylation of simian immunodeficiency virus influences immune-tissue targeting during primary infection, leading to immunodeficiency or viral control.

Authors:  Chie Sugimoto; Shinichiro Nakamura; Shoko I Hagen; Yasuko Tsunetsugu-Yokota; Francois Villinger; Aftab A Ansari; Yasuo Suzuki; Naoki Yamamoto; Yoshiyuki Nagai; Louis J Picker; Kazuyasu Mori
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

Review 8.  Interplay between HIV-1 innate sensing and restriction in mucosal dendritic cells: balancing defense and viral transmission.

Authors:  Nina Hertoghs; Teunis B H Geijtenbeek; Carla M S Ribeiro
Journal:  Curr Opin Virol       Date:  2017-01-21       Impact factor: 7.090

9.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

10.  Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS.

Authors:  R C Desrosiers; A Hansen-Moosa; K Mori; D P Bouvier; N W King; M D Daniel; D J Ringler
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

View more
  2 in total

Review 1.  Targeting natural killer cells to enhance vaccine responses.

Authors:  Andrew Cox; Hilal Cevik; H Alex Feldman; Laura M Canaday; Nora Lakes; Stephen N Waggoner
Journal:  Trends Pharmacol Sci       Date:  2021-07-23       Impact factor: 17.638

2.  Cytokine Adjuvants IL-7 and IL-15 Improve Humoral Responses of a SHIV LentiDNA Vaccine in Animal Models.

Authors:  Laury-Anne Leroy; Alice Mac Donald; Aditi Kandlur; Deepanwita Bose; Peng Xiao; Jean Gagnon; François Villinger; Yahia Chebloune
Journal:  Vaccines (Basel)       Date:  2022-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.